Capital International Investors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-876,564
| Closed | -$493M | – | 476 |
|
|
2025
Q3 | $493M | Sell |
876,564
-2,288,699
| -72% | -$1.29B | 0.08% | 173 |
|
|
2025
Q2 | $1.66B | Sell |
3,165,263
-823,869
| -21% | -$460M | 0.29% | 83 |
|
|
2025
Q1 | $2.53B | Sell |
3,989,132
-747,797
| -16% | -$514M | 0.5% | 50 |
|
|
2024
Q4 | $3.37B | Buy |
4,736,929
+1,390,534
| +42% | +$1.17B | 0.63% | 39 |
|
|
2024
Q3 | $3.52B | Buy |
3,346,395
+212,273
| +7% | +$236M | 0.68% | 37 |
|
|
2024
Q2 | $3.29B | Buy |
3,134,122
+5,112
| +0.2% | +$4.96M | 0.68% | 40 |
|
|
2024
Q1 | $3.01B | Buy |
3,129,010
+213,038
| +7% | +$203M | 0.61% | 45 |
|
|
2023
Q4 | $2.56B | Sell |
2,915,972
-58,366
| -2% | -$48.1M | 0.57% | 47 |
|
|
2023
Q3 | $2.45B | Buy |
2,974,338
+17,723
| +0.6% | +$13.9M | 0.62% | 42 |
|
|
2023
Q2 | $2.12B | Buy |
2,956,615
+803,143
| +37% | +$619M | 0.51% | 53 |
|
|
2023
Q1 | $1.77B | Buy |
2,153,472
+623,529
| +41% | +$470M | 0.46% | 67 |
|
|
2022
Q4 | $1.1B | Sell |
1,529,943
-237,193
| -13% | -$175M | 0.3% | 92 |
|
|
2022
Q3 | $1.22B | Sell |
1,767,136
-24,799
| -1% | -$15.6M | 0.36% | 77 |
|
|
2022
Q2 | $1.06B | Buy |
1,791,935
+108,036
| +6% | +$70.2M | 0.29% | 96 |
|
|
2022
Q1 | $1.18B | Buy |
1,683,899
+1,417,899
| +533% | +$897M | 0.27% | 102 |
|
|
2021
Q4 | $168M | Sell |
266,000
-865,968
| -77% | -$532M | 0.04% | 282 |
|
|
2021
Q3 | $685M | Sell |
1,131,968
-158,178
| -12% | -$98.2M | 0.16% | 139 |
|
|
2021
Q2 | $721M | Sell |
1,290,146
-15
| -0% | -$7.6K | 0.16% | 134 |
|
|
2021
Q1 | $610M | Sell |
1,290,161
-74,665
| -5% | -$36.4M | 0.15% | 142 |
|
|
2020
Q4 | $659M | Sell |
1,364,826
-78,158
| -5% | -$42.2M | 0.18% | 129 |
|
|
2020
Q3 | $808M | Sell |
1,442,984
-127,490
| -8% | -$77.3M | 0.25% | 102 |
|
|
2020
Q2 | $979M | Sell |
1,570,474
-51,741
| -3% | -$29.4M | 0.32% | 81 |
|
|
2020
Q1 | $792M | Buy |
1,622,215
+104,782
| +7% | +$43.2M | 0.32% | 80 |
|
|
2019
Q4 | $570M | Buy |
1,517,433
+503
| +0% | +$169K | 0.19% | 126 |
|
|
2019
Q3 | $421M | Buy |
1,516,930
+21
| +0% | +$6.21K | 0.16% | 138 |
|
|
2019
Q2 | $475M | Sell |
1,516,909
-62,205
| -4% | -$20.7M | 0.19% | 125 |
|
|
2019
Q1 | $648M | Buy |
1,579,114
+50,002
| +3% | +$20.6M | 0.28% | 98 |
|
|
2018
Q4 | $571M | Sell |
1,529,112
-211,000
| -12% | -$77.2M | 0.28% | 92 |
|
|
2018
Q3 | $703M | Buy |
+1,740,112
| New | +$662M | 0.32% | 84 |
|
|
2016
Q4 | – | Sell |
-93,810
| Closed | -$37.7M | – | 249 |
|
|
2016
Q3 | $37.7M | Buy |
93,810
+368
| +0.4% | +$148K | 0.05% | 211 |
|
|
2016
Q2 | $32.6M | Buy |
93,442
+109
| +0.1% | +$42K | 0.05% | 215 |
|
|
2016
Q1 | $33.6M | Buy |
93,333
+44
| +0% | +$18.1K | 0.05% | 214 |
|
|
2015
Q4 | $50.6M | Buy |
+93,289
| New | +$50.5M | 0.08% | 198 |
|
|
2015
Q3 | – | Sell |
-36
| Closed | -$18K | – | 269 |
|
|
2015
Q2 | $18K | Buy |
+36
| New | +$17.6K | ﹤0.01% | 256 |
|
Other funds holding REGN
N
Capital International Investors's REGN Position: Q4 2025 in Review
Capital International Investors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 876,564 shares — an estimated $493M sold.
Capital International Investors first reported a position in REGN in Q2 2015 and held it in 34 quarters. The position peaked at $3.52B in Q3 2024. 1,386 funds tracked by Wall St. Rank hold REGN as of Q4 2025.
- Capital International Investors reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Capital International Investors sold 876,564 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $493M.
- Capital International Investors first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 34 quarters.
- Capital International Investors's Regeneron Pharmaceuticals position peaked at $3.52B in Q3 2024.
- 1,386 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.
Based on Capital International Investors's 13F filing for Q4 2025, filed 11 Feb 2026.